About Meditab Specialities Limited
Data last updated:
Meditab Specialities Limited is a public limited company based in Mumbai, Maharashtra, India, a subsidiary of Cipla Limited. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 11 December 1996 and has been in existence for over 30 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U23240MH1996PLC104442. Its GSTIN is 27AAACM6124A1Z1 (Maharashtra). The company holds 9 GST registrations, of which 6 are active.
The company has an authorised share capital of ₹1 Cr and a paid-up capital of ₹80.86 Lakh. It was formerly known as Meditab Specialities Private Limited. It is led by directors including Sanjay Kumar Mishra (Managing Director) and Dinesh Ramniranjan Jain.
Its last annual general meeting (AGM) was held on 18 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Tower A 1st Floor Peninsula Business Park Ganpatrao Kadam Marg Lower Parel, Mumbai, Maharashtra, India – 400013.
As per the financials filed for FY 2025, the company reported a revenue of ₹40.03 Cr, a decline of 90% compared to the previous year. For the same year it recorded a net profit of ₹8.94 Cr (net margin 22.3%) and EBITDA of ₹14 Cr (EBITDA margin 35%). Revenue has grown at a compounded annual rate (CAGR) of 46% over three years and 5% over five years.
The company has about 126 employees on its provident fund (EPFO) records. Its group structure includes 2 subsidiaries.
Court records list 19 cases involving the company, including 11 filed by the company and 9 filed against it; 5 cases are pending. The company has 4 deals on record (2 rights issues, 1 acquisition, 1 secondary share transfer); the latest was in July 2021. Its 7 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 4 smaller; the largest is Alkimia Pharma-Chem Private Limited with revenue of ₹40.2 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website cipla.com.
Company details
CIN history
Meditab Specialities has one previous CIN (Corporate Identification Number): U23240MH1996PTC104442. The current CIN is U23240MH1996PLC104442, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U23240MH1996PLC104442 | Current |
| U23240MH1996PTC104442 | Previous |
Contact details
Meditab Specialities Limited's registered office is in Mumbai, Maharashtra. Its website is cipla.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressTower A 1st Floor Peninsula Business Park Ganpatrao Kadam Marg Lower Parel, Mumbai, Maharashtra, India – 400013
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Meditab Specialities Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Meditab Specialities is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Meditab Specialities Limited, buy the company report.
Financials of Meditab Specialities Limited
FY 2025 filings availableMeditab Specialities Limited reported revenue of ₹40.03 Cr (down 90% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue fell 90% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 5%. EBITDA fell 96% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹14 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹8.94 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 35% | ||||
| Net Profit Margin | 22.3% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Meditab Specialities Limited, buy the company report.
Board of directors and KMP of Meditab Specialities Limited
Meditab Specialities Limited currently reports 4 directors and 1 key managerial person. 16 former directors have served the organization.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Dinesh Ramniranjan Jain Also directs: Aspergen Limited, Cipla Pharmaceuticals Limited, Jay Precision Pharmaceuticals Private Limited and 2 more | Director | 03 Jan 2019 | 7 Years 9 Months | Current |
| Anisha Naresh Udeshi | Director | 23 Aug 2021 | 5 Years 2 Months | Current |
| Sanjay Kumar Mishra Also directs: Medispray Laboratories Private Limited | Managing Director | 21 Oct 2022 | 4 Years 0 Months | Current |
| Girish Zamwar Also directs: Clean Max Auriga Power LLP, Sitec Labs Limited | Cfo | 05 Mar 2020 | 6 Years 7 Months | Current |
| Rajendra Kumar Chopra Also directs: Cipla Pharmaceuticals Limited, Medispray Laboratories Private Limited, Cipla Digital Health Limited and 3 more | Director | 11 Nov 2024 | 1 Years 11 Months | Current |
Peer comparison
Meditab Specialities Limited is compared with the 7 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Alkimia Pharma-Chem Private Limited | ₹40.2 Cr (FY 2025) | 975.0% | Hyderabad, Telangana, India | |||
| Integrated Laboratories Private Limited | ₹40.11 Cr (FY 2024) | 24.0% | Sirmour, Himachal Pradesh, India | |||
| Vip Pharmaceuticals Private Limited | ₹40.07 Cr (FY 2025) | 6.0% | New Delhi, Delhi, India | |||
| Meditab Specialities Limitedthis company | ₹40.03 Cr (FY 2025) | ₹8.94 Cr | 22.3% | -90.0% | 126 | Mumbai, Maharashtra, India |
| Stellar Formulations Industries Private Limited | ₹39.96 Cr (FY 2025) | 11.0% | Vadodara, Gujarat, India | |||
| Zenith Enzymatic Drugs Private Limited | ₹39.93 Cr (FY 2024) | 6.0% | Pune, Maharashtra, India | |||
| Vanelloid Private Limited | ₹39.6 Cr (FY 2024) | 11.0% | Ludhiana, Punjab, India | |||
| MMC Health Care Limited | ₹39.6 Cr (FY 2024) | -17.0% | Chennai, Tamil Nadu, India |
To see the full peer comparison of Meditab Specialities Limited, buy the company report.
Auditor
Meditab Specialities Limited is audited by Walker Chandiok & Co LLP for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Walker Chandiok & Co LLP | FY 2023 | 001076N/N500013 |
Shareholding
The shareholding of Meditab Specialities Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Meditab Specialities Limited, buy the company report.
Deals & funding
Meditab Specialities Limited has 4 deals on record (2 rights issues, 1 acquisition, 1 secondary share transfer); the latest was in July 2021.
Deals on record (4 of 4)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jul 2021 | Acquisition | Undisclosed | Buyer: Rubicon Research Limited Seller: Meditab Specialities Limited |
| Aug 2019 | Rights issue | ₹224.15 Cr | Investors: Cipla Limited |
| Sep 2014 | Rights issue | ₹24.71 Cr | Investors: Cipla Limited |
| Oct 2010 | Secondary share transfer | Undisclosed | Buyer: Cipla Limited Seller: Riddhi Siddhi Chemicals Private Limited, MN Rajkumar Garments Pvt Ltd , Premratan Exports Pvt Ltd |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Meditab Specialities Limited has 19 court cases on record: 11 filed by Meditab Specialities, 9 filed against it. 5 cases are pending and 14 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 16 | 8 | 5 |
| Supreme Court | 2 | 0 | 0 |
| District courts | 1 | 1 | 0 |
Cases on record (5 of 19)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court, MAHARASHTRA | Interim or miscellaneous application | Filed against the company by Meditab Specialities Ltd | Pending |
| High Court, MAHARASHTRA | Court case (CARBP) | Filed by the company against Ashoka Buildcon Limited | Pending |
| High Court, MAHARASHTRA | Interim or miscellaneous application | Filed by the company against Meditab Specialities Ltd | Pending |
| High Court, MAHARASHTRA | Interim or miscellaneous application | Filed by the company against Ashoka Buildcon Limited | Pending |
| High Court, MAHARASHTRA | Interim or miscellaneous application | Filed by the company against Ashoka Buildcon Limited | Disposed |
To see the full case history of Meditab Specialities Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Meditab Specialities Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Group structure & subsidiaries
Meditab Specialities has 2 subsidiary companies and 1 associated company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares held |
|---|---|---|
| Medispray Laboratories Private Limited | U52311GA1992PTC002801 | |
| Sitec Labs Limited | U74999MH2000PLC129210 |
To see the full group structure of Meditab Specialities Limited, buy the company report.
Employees & EPFO
Meditab Specialities Limited has a workforce of 126 employees on its EPFO records as of Apr 02, 2024, across 2 active EPFO establishments.
GST
Meditab Specialities has 9 GST registrations: 6 active and 3 cancelled or inactive. The first 4 active GSTINs are listed below.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACM6124A1Z1 | Maharashtra | Active | 01 Jul 2017 |
| 11AAACM6124A1ZE | Sikkim | Active | 01 Jul 2017 |
| 24AAACM6124A1Z7 | Gujarat | Active | 01 Jul 2017 |
| 30AAACM6124A1ZE | Goa | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Meditab Specialities Limited, buy the company report.
Recent activity
Meditab Specialities Limited has 19 board changes on record since 2009: 5 appointments and 14 cessations. The latest: Rajendra Kumar Chopra ceased to be Additional Director on 17 Sep 2025.
10 earlier events are in the company report.
News
Frequently asked questions
Meditab Specialities is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 11 December 1996 (30+ years old) and is registered under CIN U23240MH1996PLC104442.
Meditab Specialities has 5 current directors and KMP:
- Sanjay Kumar Mishra - Managing Director
- Dinesh Ramniranjan Jain - Director
- Anisha Naresh Udeshi - Director
- Rajendra Kumar Chopra - Director
- Girish Zamwar - Cfo
The latest financial statements of Meditab Specialities on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 18 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Meditab Specialities is 27AAACM6124A1Z1, registered in Maharashtra. The company has 9 GST registrations in all, of which 6 are active and 3 are cancelled or inactive. Other active GSTINs include 11AAACM6124A1ZE (Sikkim), 24AAACM6124A1Z7 (Gujarat), 30AAACM6124A1ZE (Goa).
The CIN (Corporate Identification Number) of Meditab Specialities is U23240MH1996PLC104442. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Meditab Specialities has 19 court cases on record: 11 filed by the company and 9 filed against it. 5 are pending. Most are in the high courts.
Meditab Specialities was incorporated on 11 December 1996, making it 30+ years old. It is registered with the Registrar of Companies, Mumbai.
Meditab Specialities has 4 deals on record (2 rights issues, 1 acquisition, 1 secondary share transfer); the latest was in July 2021.
The peers of Meditab Specialities by revenue are Alkimia Pharma-Chem Private Limited, Integrated Laboratories Private Limited, Vip Pharmaceuticals Private Limited, Stellar Formulations Industries Private Limited, Zenith Enzymatic Drugs Private Limited and 2 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Rajendra Kumar Chopra ceased to be Additional Director on 17 Sep 2025. Rajendra Kumar Chopra was appointed as Director on 11 Nov 2024. Sanjay Kumar Mishra was appointed as Managing Director on 21 Oct 2022. Meditab Specialities has 19 board changes on record in total.
Meditab Specialities can be reached through the website cipla.com. Its registered office is in Mumbai, Maharashtra, India.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
